You just read:

FDA Grants Orphan Drug Designation to APR Applied Pharma Research's Investigational Drug for the Treatment of Epidermolysis Bullosa

News provided by

APR Applied Pharma Research s.a.

04 Dec, 2019, 11:22 GMT